Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea

This will be a single center, comparative, randomized, double-blind, phase III trial designed to evaluate the efficacy of the NK-1 antagonist, aprepitant (MK-869), in combination with ondansetron and dexamethasone in the prevention of acute and delayed nausea and vomiting compared to ondansetron and dexamethasone in patients receiving highly emetogenic preparative regimens prior to autologous or allogeneic (related and unrelated) stem cell transplantation.

Patients will be randomized to one of two treatments: dexamethasone 10 mg IV once daily and ondansetron 8 mg orally every 8 hours on each day of the preparative regimen plus one additional day vs. 7.5 mg IV once daily and ondansetron 8 mg orally every 8 hours on each day of the preparative regimen plus one additional day combined with aprepitant, 125 mg orally on the first day of their preparative regimen followed by 80 mg daily on each remaining day of the preparative regimen plus three additional days.

Inclusion criteria

• Diagnosis of cancer, admitted for myelosupppresive stem cell transplantation. Included preparative regimens include: TBI/VP16/CY, TBI/CY, BU/CY (PO & IV), and BCV
• Age 18 or older
• Alcohol intake <100 gm/d for the last year (< approximately 5 drinks per day)
• Renal function: estimated or measured CrCl 50 ml/min
• Liver function: T.Bili <1.5, AST < 2x ULN, unless due to disease
• Able to swallow tablets and capsules

Exclusion criteria

• Age < 18
• High alcohol intake [> 100 gm/d in the last year]
• Allergy or intolerance to: ondansetron or dexamethasone
• Renal dysfunction [measured or estimated CrCl < 50 ml/min]
• Liver dysfunction [T.Bili > 1.5, AST > 2x ULN, unless due to disease]
• Inability to swallow tablets or capsules
• Concurrent condition requiring systemic steroid use
• Nonmyeloablative SCT, patients receiving the conditioning regimens not included [see inclusion criteria]
• History of anticipatory nausea and vomiting